This study aimed to elucidate the physiological role of the RAS in GLP-1-mediated improvement of NAFLD, providing evidence for the treatment of NAFLD using GLP-1-based drugs. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatotic liver disease.